NASDAQ: AIDX20/20 Biolabs Inc Stock
$1.21-0.08 (-6.2%)
Updated May 21, 2026
AIDX Price
$1.21
Fair Value Price
N/A
Market Cap
$12.79M
52 Week Low
$1.19
52 Week High
$50.00
P/E
N/A
P/B
5.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.19
Operating Cash Flow
N/A
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AIDX Overview
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AIDX's potential to beat the market
- AIDX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AIDX
RankedUnranked of 95
RankedUnranked of 95
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.50 | A | |
| $38.58 | A | |
| $25.63 | A |
Be the first to know about important AIDX news, forecast changes, insider trades & much more!
AIDX News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AIDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AIDX is poor value based on its book value relative to its share price (5.01x), compared to the US Medical Devices industry average (3.04x)
P/B vs Industry Valuation
AIDX's short-term assets ($4.70M) exceed its short-term liabilities ($2.58M)
Short-term Liabilities Financials
AIDX's short-term assets ($4.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more AIDX due diligence checks available for Premium users.
Valuation
AIDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.01x
Industry
3.04x
AIDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AIDX's financial health
Profit margin
Revenue
$353.4k
Net Income
-$2.2M
Profit Margin
-600.1%
Assets to liabilities
Assets
$5.8M
Liabilities
$3.0M
Debt to equity
1.19
AIDX's short-term assets ($4.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AIDX's short-term assets ($4.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AIDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
-$5.4k
Financing
$4.5M
AIDX vs Medical Device Stocks
20/20 Biolabs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.